Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer, covers the month of October 2021. The report, dated October 6, 2021, consists solely of a press release attached as Exhibit 99.1 and incorporated by reference. The registrant is based in Jerusalem, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As this report is a procedural filing incorporating a press release, it contains no audited financial statements or specific financial data points.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The document serves to incorporate a press release by reference but does not detail the content of that release or any specific operational or financial changes within the text of the Form 6-K itself.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. While the press release is incorporated by reference, the specific content regarding future expectations or risk factors is not summarized in the provided text.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 to understand the specific announcement made on October 6, 2021.
- Verify the incorporation of this report into the company's active registration statements on Form F-3 (Registration Numbers 333-238988 and 333-239843).
- Confirm the identity of the authorized signatory, Spiros Jamas, Sc.D, Chief Executive Officer and Director.
- Check subsequent filings for any superseding information regarding the matters referenced in this press release.